Ontology highlight
ABSTRACT:
SUBMITTER: Tamay Z
PROVIDER: S-EPMC5110439 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Tamay Zeynep Z Gokcay Gulden G Dilek Fatih F Balci Mehmet Cihan MC Ozceker Deniz D Demirkol Mubeccel M Guler Nermin N
JIMD reports 20160308
Mucopolysaccharidosis type VI (MPS VI) is a progressive, chronic, and multisystem lysosomal storage disease. Enzyme replacement therapy (ERT) with the recombinant human arylsulfatase B enzyme (galsulfase [Naglazyme]) is recommended as first-line therapy. It is generally reported as safe and well tolerated. Frequently observed mild to moderate infusion-related reactions which can be easily handled by reducing or interrupting the infusion and/or administering additional antihistamines, antipyretic ...[more]